ArticleACS omega2025
PI3K-Seeker: A Machine Learning-Powered Web Tool to Discover PI3K Inhibitors.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphatidylinositol 3-kinases (PI3Ks) play a crucial role in human metabolism, and their dysregulation contributes to the development of several metabolic disorders, including cancer. Despite advances in experimental high-throughput screening, discovering new therapeutic agents remains challenging and costly. In this study, we developed PI3K-Seeker, a web server based on a two-stage prediction process to find new PI3K inhibitors. The first stage eliminates nonbinders, while the second refines the selection, leaving only molecules with a high probability of being potent inhibitors. Models were trained using the XGBoost algorithm and PubChem fingerprints extracted from distinct datasets. In the first stage of classification, the model showed impressive metrics (MCC: 0.917, AUC-ROC: 0.993, and ACC: 0.917). In the second stage, the data enhancement, the model trained also performed exceptionally well (MCC: 0.939, AUC-ROC: 0.956, and ACC: 0.994). The PI3K-Seeker is a user-friendly web server suitable for a large set of compounds, available at http://www.ufrgs.br/labec/pi3k-seeker/.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.